Oncology & Cancer
Squaring up to silent tumors: The research burden of pancreatic cancer
By the time a pancreatic tumor begins to cause symptoms, it is usually pretty advanced, since many of the tumors are 'silent."
Mar 2, 2020
0
85
News tagged with overall survival
Oncology & Cancer
Immune-stimulating drug before surgery shows promise in early-stage pancreatic cancer
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study ...
Apr 11, 2021
0
28
Medications
Relugolix superior to leuprolide in advanced prostate cancer
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
Oncology & Cancer
Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo+bev vs 13.4 months for those treated with sorafenib alone, the current standard treatment (HR, 0.66 [95% CI, 0.52-0.85]; P=0.0009). ...
Feb 6, 2021
0
4
Oncology & Cancer
Survival up for chronic lymphocytic leukemia 1995 to 2017
(HealthDay)—For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia & Lymphoma.
Dec 26, 2019
0
6
Oncology & Cancer
Immunotherapy for brain cancer metastases shows clinical benefit
In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that 42 percent of patients with metastatic brain cancer benefited from the therapy, with seven patients in the trial surviving ...
Jun 2, 2023
0
97
Medications
Improving drug therapy for relapsed leukemia
A combination of two drugs showed promise in treating relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, according to a Northwestern Medicine study published ...
Sep 14, 2022
0
33
Oncology & Cancer
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients ...
Jun 16, 2023
0
28
Medical research
Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations
The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according ...
Sep 9, 2023
0
18
Oncology & Cancer
Liquid biopsy may help identify which patients with non-small cell lung cancer will benefit most from radiation
A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has spread beyond the lungs are most likely to benefit from targeted, high-dose radiation, rather than drug-based therapy, ...
Oct 2, 2023
0
19
